Editorial: Liquid biopsy biomarkers for cancer detection, treatment monitoring, and clinical outcome prediction

Infographic illustrating liquid biopsy as a dynamic window into cancer, highlighting multiple biomarker sources such as tumor cells, DNA, RNA, extracellular vesicles, immune and stromal cells, and platelets. A workflow depicts integrated, longitudinal sampling, multi-omics monitoring, data interpretation, and timely decision-making in precision oncology. Clinical impact box lists benefits: better detection, risk stratification, treatment guidance, and outcomes. Banner below states liquid biopsy advances from detecting cancer signals to providing dynamic, actionable insights for guiding oncology and improving care.